Core Viewpoint - The company is utilizing its own funds to pay for investment projects and will subsequently replace these funds with raised capital, ensuring efficient use of funds and smooth project implementation [1][6][7] Fundraising Overview - The company issued 16,229,100 shares at a par value of 1.00 RMB per share, raising a total of approximately 1.31 billion RMB after deducting issuance costs [1][2] - The total expected investment for the projects funded by the raised capital is approximately 434.36 million RMB [2][3] Investment Project Details - The company has established a dedicated account for the raised funds, which are fully stored in this account and are subject to a tripartite/four-party supervision agreement with the sponsor and the bank [2] - The net amount raised from the initial public offering is 1,308,998,865.06 RMB, with excess funds available for investment [3] Reasons for Using Own Funds - The company’s U.S. subsidiary, Bepharm Scientific Inc, initially paid for automation equipment costing 1.5 million USD due to delays in foreign investment filing [4][5] - Payments for salaries, bonuses, and other operational costs must be made from the company's basic deposit account, not from the raised funds account, to comply with banking regulations [4] - Frequent small payments for project-related expenses would complicate fund management if made directly from the raised funds account, thus necessitating the use of own funds initially [5] Operational Process for Fund Replacement - The company will submit payment requests for project-related expenses, initially using its own funds, and will replace these with raised funds within six months following the payment [6] - A detailed record will be maintained to ensure compliance with the investment project requirements [6] Impact on Daily Operations - The use of own funds followed by replacement with raised funds is expected to enhance the efficiency of fund utilization and project implementation without affecting the normal operation of investment projects [6][7] Review Procedures - The board of directors has approved the use of own funds for project expenses, ensuring compliance with relevant regulations and confirming that this does not alter the intended use of raised funds [6][7]

Core Viewpoint - The company has announced the use of its own funds to pay for part of the fundraising investment projects, which will later be replaced with equivalent amounts from the raised funds, ensuring the smooth implementation of the projects [1][5][6] Fundraising Basic Information - The company raised a total of 680 million RMB through a non-public offering of A-shares, with the funds deposited in designated bank accounts [1][2] - The total amount of funds raised after deducting issuance costs is 680 million RMB, with additional amounts for taxes and fees [1] Investment Project Details - The initial investment projects included the "New Media Commercial Big Data Platform Construction Project" and the "WEIQ New Media Marketing Cloud Platform Upgrade Project," with a total investment of 251.51 million RMB and intended fundraising of 207.19 million RMB [2] - The projects were later changed to "Content Marketing Ecosystem Platform Upgrade Project" and "Innovative Technology Module Upgrade Project," with a revised total investment of 131.96 million RMB and intended fundraising of 126.24 million RMB [2][3] Reasons for Using Own Funds - The company needs to use its own funds for salary payments and other operational costs to comply with banking regulations, as using raised funds directly for these purposes is impractical [3][4] - This approach aims to enhance the efficiency of fund usage and ensure the smooth progress of the investment projects [3][5] Operational Process for Fund Replacement - The company will transfer the equivalent amount from the raised funds to its own accounts within six months after using its own funds for project payments [4][5] Approval and Opinions - The board and supervisory committee have approved the use of own funds for project payments, confirming that this does not alter the intended use of raised funds or harm shareholder interests [5][6] - The sponsor has also expressed no objections to the company's plan, affirming compliance with relevant regulations [5]

证券代码：600930 证券简称：华电新能 公告编号：2025-006 华电新能源集团股份有限公司 公司监事会认为：公司本次使用行使超额配售选择权对应的募集资金置换预先投入募投项目的自筹资 金，提高了募集资金使用效率，符合全体股东利益。上述事项内容及审议程序符合《上海证券交易所股 票上市规则》《上海证券交易所上市公司自律监管指引第1号一一规范运作》等相关法律法规的有关规 定，不影响募集资金投资项目的正常进行，不存在变相改变募集资金用途和损害股东利益的情形。公司 监事会同意公司使用行使超额配售选择权对应的募集资金235,252.84万元置换预先投入募投项目的自筹 资金。 表决情况：3票同意、0票反对、0票弃权。 特此公告。 一、 监事会会议召开情况 2025年8月18日，华电新能源集团股份有限公司（以下简称"公司"）第一届监事会第十二次会议以通讯 方式举行。本次会议通知于2025年8月15日以通讯方式向全体监事发出。本次会议应出席监事3名，亲自 出席监事3名，会议由邵福生主席主持。本次会议的召开符合《公司法》《公司章程》等法规及规范性 文件的有关规定。 二、监事会会议审议情况 本次会议经与会监事充分审议并有效表 ...

Summary of Key Points Core Viewpoint - The company, Anhui Xindong Lian Ke Micro System Co., Ltd., is utilizing its own funds to pay for investment projects and will replace these expenditures with raised funds in an equal amount, which has been reviewed and approved by the sponsor and supervisory board [1][6]. Group 1: Fundraising Overview - The company has issued 55.21 million shares at a price of 26.74 RMB per share, raising a total of 1,476.32 million RMB, with a net amount of 1,354.36 million RMB after deducting issuance costs [1]. - The raised funds are stored in a special account approved by the company's board and are subject to a tripartite supervision agreement with the sponsor and the commercial bank [2]. Group 2: Investment Project Details - The total investment for the fundraising projects is 100 million RMB, with the same amount planned to be used from the raised funds [2][3]. - The company has approved changes to the investment projects, extending the implementation period and adjusting the investment structure to include a new project for the development and industrialization of Inertial Measurement Units (IMU) [2][3]. Group 3: Reasons for Using Own Funds - The company needs to use its own funds for certain expenditures due to regulatory requirements, such as salary payments and tax obligations, which cannot be processed through the fundraising account [4][5]. - The use of own funds allows for more efficient management of project payments, especially when dealing with multiple projects sharing the same location [5]. Group 4: Operational Process - The company will compile a detailed list of expenditures paid with its own funds and will subsequently transfer an equal amount from the fundraising account to replace these expenditures [5]. - Continuous supervision will be conducted to ensure compliance with the replacement process, with the company and the bank cooperating with the sponsor's inquiries [5]. Group 5: Impact and Approval - The use of own funds is expected to enhance the efficiency of fund utilization and will not affect the normal implementation of the investment projects [6]. - The board and supervisory committee have reviewed and approved the use of own funds for project payments, confirming that it aligns with regulatory requirements and does not alter the intended use of raised funds [6][7].

Core Viewpoint - The company, Shanghai Hehui Optoelectronics Co., Ltd., is utilizing its own funds to pay for part of the fundraising investment projects and will subsequently replace these with equivalent amounts from the raised funds, ensuring compliance with relevant regulations and maintaining operational efficiency [1][6]. Summary of Fundraising Situation - The company was approved to publicly issue shares, with a total of 3,083,660,725 shares issued at a price of 2.65 RMB per share, resulting in a net fundraising amount of approximately 8 billion RMB [1]. - As of June 30, 2025, the total committed investment for the sixth-generation AMOLED production line expansion project is approximately 800 million RMB, with cumulative investment amounting to about 663 million RMB [2]. Fundraising Investment Project Process - The company will initially use its own funds to pay for overseas equipment and services due to restrictions on the fundraising account, and will later replace these with raised funds [2][4]. - The finance department will track payments made with its own funds and will compile monthly summaries to ensure compliance with the company's fundraising management regulations [2][4]. Impact on Daily Operations - The approach of using own funds for project payments is expected to enhance fund utilization efficiency and will not affect the normal operation of fundraising investment projects or harm the interests of the company and its shareholders [4]. Decision-Making Procedures - The company’s board and supervisory committee approved the use of own funds for project payments and subsequent replacement with raised funds, ensuring compliance with legal and regulatory requirements [5]. Supervisory Committee Opinion - The supervisory committee agrees that the use of own funds followed by replacement with raised funds aligns with relevant regulations and does not alter the purpose of the raised funds or harm shareholder interests [5][6]. Sponsor Institution's Verification Opinion - The sponsor institution confirms that the company has followed necessary procedures and that the use of own funds for project payments will not disrupt the normal progress of fundraising investment projects [6].

申万宏源证券承销保荐有限责任公司 关于 TCL 科技集团股份有限公司 使用募集资金置换预先支付现金对价的 自有及自筹资金的核查意见 独立财务顾问 二〇二五年八月 TCL 科技集团股份有限公司（以下简称"TCL 科技""上市公司"或"公 司"）发行股份及支付现金购买深圳市重大产业发展一期基金有限公司持有的深 圳市华星光电半导体显示技术有限公司 21.5311%股权，并向不超过 35 名（含） 符合条件的特定对象发行股份募集配套资金（以下简称"本次交易"），申万宏 源证券承销保荐有限责任公司（以下简称"申万宏源承销保荐"或"独立财务顾 问"）作为上市公司的独立财务顾问，根据《上市公司募集资金监管规则》《深 圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作（2025 年修订）》等相关法律法规和规范性文件的规定，对上市公司使用募集资金置换 预先支付现金对价的自有及自筹资金事项进行了审慎核查，具体情况如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意 TCL 科技集团股份有限公司发行股 份购买资产并募集配套资金注册的批复》（证监许可〔2025〕1326 号）同意，公 司向特定对象发行人民 ...

Meeting Overview - The third meeting of the board of directors of Jiangsu Aidi Pharmaceutical Group Co., Ltd. was held on August 14, 2025, with all 7 directors present, complying with relevant regulations [1]. Agenda Items - The board approved the adjustment of the 2025 stock option incentive plan, reducing the number of incentive recipients from 45 to 43 and the total stock options from 9.1 million to 8.96 million due to the departure of 2 recipients [1][2]. - The board agreed to grant stock options to the 2025 incentive recipients, with the grant date set for August 14, 2025, and a total of 8.96 million stock options to be issued at an exercise price of 13.01 yuan per share [2][3]. - The board approved the use of self-owned funds and bank acceptance bills to finance fundraising projects, which will be replaced by the raised funds, enhancing fund efficiency and reducing costs [3][4].

证券代码：603262 证券简称：技源集团 公告编号：2025-005 技源集团股份有限公司 关于使用募集资金置换先期已支付发行费用的 自筹资金的公告 一、募集资金基本情况 经中国证券监督管理委员会《关于同意技源集团股份有限公司首次公开发行股 票注册的批复》（证监许可〔2025〕799 号）同意注册，并经上海证券交易所同意， 公司向社会公开发行人民币普通股（A 股）5,001.00 万股，发行价格为 10.88 元/股， 本次发行募集资金总额为 54,410.88 万元，扣除发行费用 6,429.06 万元（不含增值税） 后，募集资金净额为 47,981.82 万元。立信会计师事务所（特殊普通合伙）对公司本 次公开发行新股的资金到位情况进行了审验并出具了《验资报告》 （信会师报字[2025] 第 ZK10290 号）。公司已对上述募集资金进行专户存储管理，并已与保荐机构、募 集资金专户监管银行签订募集资金监管协议。 二、募集资金投资项目情况及调整情况 根据《技源集团股份有限公司首次公开发行股票并在主板上市招股说明书》及 《技源集团股份有限公司关于调整部分募投项目金额的公告》，首次公开发行股票 所募集的资金扣除 ...

东方证券股份有限公司 关于技源集团股份有限公司 使用募集资金置换先期已支付发行费用的自筹资金 的核查意见 东方证券股份有限公司（以下简称"保荐机构"）作为技源集团股份有限公司（简 称"技源集团"、"公司"）首次公开发行股票并在主板上市的保荐机构，根据《证 券发行上市保荐业务管理办法》《上市公司募集资金监管规则》《上海证券交易所 股票上市规则》《上海证券交易所上市公司自律监管指引第1号——规范运作》等有 关法律法规和规范性文件的规定，对技源集团使用募集资金置换先期已支付发行 费用的自筹资金的事项进行了审慎核查，具体情况如下： 四、履行的审议程序 公司于2025年8月12日召开了第二届第四次董事会、第二届第三次监事会，分 别审议通过了《关于使用募集资金置换先期已支付发行费用的自筹资金的议案》， 同意使用募集资金置换先期已支付发行费用的自筹资金。 上述事项在董事会审批权限范围内，无需提交股东大会审议。 一、募集资金基本情况 经中国证券监督管理委员会《关于同意技源集团股份有限公司首次公开发行 股票注册的批复》 （证监许可〔2025〕799号）同意注册，并经上海证券交易所同 意，公司向社会公开发行人民币普通股（A股）5 ...

证券代码：001388 证券简称：信通电子 公告编号：2025-003 山东信通电子股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 一、董事会会议召开情况 山东信通电子股份有限公司（以下简称"公司"）第四届董事会第十五次会议于 月7日通过邮件方式送达各位董事。本次会议应出席董事7名，实际出席董事7名，其 中董事郭炉先生、王树亭先生、刘元锁先生以通讯表决方式出席。本次会议由董事长 李全用先生召集并主持，公司部分监事和高级管理人员列席了本次会议。会议的召集、 召开及表决程序符合《中华人民共和国公司法》（以下简称"《公司法》"）等法律、 法规、规范性文件和《公司章程》的有关规定，会议合法有效。 二、董事会会议审议情况 与会董事认真审议，通过了如下议案： 公 司以募集资金置换 预先投 入募投项目及 已支付发行费用的自 筹资金合 计 已支付发行费用的自筹资金金额为2,758.14万元（不含增值税）。本次募集资金置换 事项符合《上市公司募集资金监管规则》《深圳证券交易所上市公司自律监管指引第 常进行，也不存在变相改变募集资金用途的情形，募集资金置换的时间距募 ...